FMC Corporation

▲ Bull Case

• ◆Cyazypyr resilience + Isoflex S-curve: If Cyazypyr re-accelerates (+15%+ YoY) as stewardship-driven farmer preference returns, and Isoflex Year-4 acreage data shows step-function adoption, total new-product revenue could exceed $1B by FY2028 vs. $700M in base case, supporting EBITDA recovery to $1B+
• ◆Deleveraging plan over-executes: India business + select licensing deals fetch $700–800M (vs. $500M base), driving net debt below $3B by end-FY2027 and triggering multiple re-rating from current ~8x to 11x EBITDA
• ◆Strategic alternatives: At $13/share / $1.6B market cap, FMC is a feasible target for Syngenta (post-IPO) or PE consortium at $18–22/share — a 'downside cushion' that limits left-tail outcomes in the severe scenario

▼ Bear Case

• ◆Diamide franchise collapse: Generic CTPR further compresses Rynaxypyr pricing -15% in FY2026 AND cannibalizes Cyazypyr via cross-resistance management failures; combined diamide revenue falls below $1B by FY2028
• ◆Equity issuance forced by Brazil weakness: BRL weakens to 6.5+, farmer credit issues delay AR collection, FCF disappoints, covenant pressure builds → $400–500M equity raise at $11–14 = ~25–35% dilution to per-share value
• ◆Permanent margin reset: EBITDA margin fails to reflate above 19% (vs. 23%+ pre-distress) because mix shift to lower-margin biologicals + generics permanence reset terminal economics; FY2030 EBITDA capped at ~$850M vs. $1.15B base

“The Street is debating two questions: (1) Is the current trough cyclical or structural? Bull view: FY2025 revenue of ~$3.9B represents unsustainably low trough that will mean-revert to ~$4.5B. Bear view: Rynaxypyr's permanent impairment has reset FMC's revenue ceiling to ~$4B and current 'trough' is closer to new normal. (2) Can FMC deleverage without equity issuance? Management says yes; covenant relief implies board believes yes; some bears believe $500M–$1B equity raise is inevitable. Q3 2026 earnings call commentary on India business sale completion + Brazil order book will largely resolve this debate. Sell-side consensus price targets range $13–$18 (JPMorgan recently raised to $16); consensus rating distribution skews Hold/Underweight with analytical community largely sitting on sidelines pending more execution evidence.”

• ◆India business sale signing (May–June 2026) — first asset sale execution evidence; binary signal on deleveraging credibility
• ◆Q2 2026 earnings (early August) — Brazil order book commentary; channel normalization confirmation; Rynaxypyr pricing data
• ◆Q3 2026 earnings (late October) — FY2026 guide tightening; FY2027 preliminary commentary; covenant compliance trajectory
• ◆Brazil safrinha 2026 results (Q4 2026) — single largest seasonal demand window for diamides; sets up FY2027 trajectory
• ◆Isoflex Year-4 acreage data (Q1 2027 release) — defining moment for new-product S-curve thesis
• ◆Cyazypyr crossing $500M annual run-rate — confirms diamide transition path versus generic CTPR pressure
• ◆Strategic alternatives announcement — low-probability but high-impact; would create binary outcome

• ◆Equity issuance to bridge covenant compliance — most destructive single risk; 25–35% per-share dilution in bear case
• ◆Continued Rynaxypyr generic erosion — pricing AND volume below current expectations
• ◆Brazil credit / FX disruption — BRL > 6.5 or farmer credit tightening hurts revenue and AR collection
• ◆Cyazypyr cannibalization by generic CTPR — generic Rynaxypyr providers expand into Cyazypyr territory via resistance management failures
• ◆Asset sale execution failure — India business sale falls through or proceeds well below $400M
• ◆Covenant amendment failure post-2027 — leverage hasn't fallen below 6.75x by Dec 2027; likely requires equity issuance condition
• ◆Diamide resistance spread — 5–10 year horizon risk impacting both Rynaxypyr and Cyazypyr
• ◆Dividend permanently eliminated — would trigger forced selling from income investors
• ◆Credit rating downgrade to HY — increases refinancing costs; may trigger forced asset sales